SUPPLEMENTARY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 17,565	$ 15,693	$ 13,749	$ 10,417	$ 14,649	$ 12,451	$ 11,050	$ 13,196	$ 57,424	$ 51,346
Costs and expenses	23,805	24,453	29,872	35,329	32,081	21,595	37,929	51,698	113,459	143,303
Loss from operations	(6,240)	(8,760)	(16,123)	(24,912)	(17,432)	(9,144)	(26,879)	(38,502)	(56,035)	(91,957)
Net loss from continuing operations	8,510	8,950	15,645	22,088	14,256	10,460	26,570	41,538	55,193	92,824
Net income from discontinued operations					3,894	927,091	18,379	15,592		964,956
Net Income (Loss)	$ (8,510)	$ (8,950)	$ (15,645)	$ (22,088)	$ (10,362)	$ 916,631	$ (8,191)	$ (25,946)	$ (55,193)	$ 872,132
Net loss from continuing operations - basic per share	$ (0.17)	$ (0.17)	$ (0.28)	$ (0.35)	$ (0.21)	$ (0.21)	$ (0.35)	$ (0.55)	$ (1.00)	$ (1.26)
Net loss from continuing operations - diluted per share	(0.17)	(0.17)	(0.28)	(0.35)	(0.21)	(0.21)	(0.35)	(0.55)	(1.00)	(1.26)
Net income from discontinued operations - basis per share					0.06	12.35	0.24	0.21		13.11
Net income from discontinued operations - diluted per share					0.06	12.35	0.24	0.21		13.11
Net income (loss) - basic (in dollars per share)	(0.17)	(0.17)	(0.28)	(0.35)	(0.15)	12.14	(0.11)	(0.34)	(1.00)	11.85
Net income (loss) per share -diluted (in dollars per share)	$ (0.17)	$ (0.17)	$ (0.28)	$ (0.35)	$ (0.15)	$ 12.14	$ (0.11)	$ (0.34)	$ (1.00)	$ 11.85
Percentage of profit share									35.00%
YUPELRI Monotherapy
Total revenue	$ 21,225	$ 20,414	$ 19,263	$ 16,434	$ 19,495	$ 18,698	$ 17,177	$ 15,283
Percentage of net sales									35.00%
Mylan
Percentage of profit share									65.00%